Apparently, a few things, so buckle up.
As many of you know, Bob Marley was no stranger to cannabis.
The autodidact spent many a year enjoying the festivals, the crowd, and the reefer to his heart’s content. So too, it seems, the legacy continues through his kin.
Damian Marley, through his unique Stony Hill Corp. (OTCQB: STNY) brand wishes to propagate that legacy with a little help from corporate America and the intelligentsia. On the surface, the matchup between reggae legend and scientist/doctor may seem far-fetched, but upon closer inspection, it makes all the sense in the world.
Stony Hill Corp. (www.stonyhillcorp.com), founded by Damian Marley, is a diversified company focused on multiple areas of the cannabis, hemp and CBD industry.
The company is focused on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, as well as media industries.
One of Stony Hill’s recent announcements, which was quietly released and most likely not on most canna-investors radars yet, was that they just launched a line of hemp-derived CBD products. What’s interesting about this launch is not that the product offering is so broad, offering roughly 14 SKU’s, but that the CBD is hemp derived.
According to their press release from October 24th, 2017 they allude to the fact that being hemp-derived may help them in their expansion efforts as they may not be affected by the same interstate and federal export laws cannabis-derived Companies face—in other words, they could manufacture in one state, and sell throughout the US, the rest of north America and globally with no issues—cannabis- based players are marooned in the State they operate in.
It is these CBD products we see the connection to STNY’s Advisory board with their illustrious medical backgrounds. CBD is said to be a compound with many medical uses stretching from inflammation reduction to pain management, and the only way to make these claims is with true medical research.
Enter Dr. James Mulé, recognized for his research and clinical trial contributions to cancer immunotherapy over the years, particularly as they apply to melanoma. With professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington he looks to take this company to the next level.
- The company Stony Hill is currently traded under ticker symbol OTCQB: STNY.
While thinly traded, it currently sits at $2.38/share with some steady support. We anticipate a potential skyrocketing share price due in part to the small float and thinly traded nature of the shares. The information we present to you here as yet to be disseminated to a broader audience, so consider yourselves early.
- Fun Fact: Dr. Mulé in his translational work in this area has helped to develop new treatments for advanced cancer patients.
His pedigree and background stretch out beyond even that. Image the potential for synergy and opportunity – particularly as legislation changes – to capitalize on this company’s potential if only at the pharmaceutical level.
Additionally, Dr. Mulé also received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland. Pedigree like this is hard to come by in the OTC/Small Cap arena.
“This key addition to the team of Dr. Mulé is something other smaller cap companies could only dream of”
As if that’s not enough the company also has a Professor and another PhD on board as well…
Professor Oded Shoseyov
is a Co-Founder of SP Nano Ltd. and serves as its Scientifi c Advisor. Prof. Shoseyov is the Scientific Founder of CBD Technologies., FuturaGene, Melodea and Bondex.
Dr. Raymond Urbanski
Dr. Raymond W. Urbanski, M.D., Ph.D. has been Chief Medical Officer at GT Biopharma, Inc. since September 2017. Dr. Urbanski oversees the development of key products in GT Biopharma’s product pipeline, including its platform targeted immunotherapy BiKE and TriKE technologies.
So it seems, Bob Marley’s son and a former medical officer as Pfizer apparently have plenty in common. Who knew?
But we digress, small cap stocks can in fact often be gamble. However, from what we have seen thus far, Stony Hill Corp (OTCQB: STNY) is on another level entirely.
A positive PR pipeline may ensue and bring further awareness to the company’s shares. With thinly traded stocks like this, explosive moves are not uncommon.
Seriously Speaking, if they can capture even a fraction of the market for treating serious diseases etc through the use of their product, the shares should catapult and leave investors knowing that “Everything little thing, it’s gona be alright.”
The Cannabis Investor is always researching new trade ideas which have the makings for large market moves. Traders are urged to follow our parent outlet, The Wealthy Venture Capitalist & The Cannabis Investor, on social media (see below) to stay apprised. We are an anti-email media outlet, and as such will only be releasing our reports/ updates/ news through Twitter and Facebook, as well as newswire.
GET BREAKING NEWS FROM US:
Join the largest Cannabis Investing page on Facebook: www.facebook.com/MMJInvestor
To receive text Message alerts when new articles are released click here:http://clk2.it/k7oF5z
Join our Email list: http://eepurl.com/bUSa71
This report/release/profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. The Wealthy Venture Capitalist and its employees are not a Registered Investment Advisors, Broker Dealers or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Sometimes human error can attribute to honest mistakes in reporting on issues regarding public companies and overall capital markets, and as such we are not responsible for the complete accuracy in these reports as the reader is required to verify all statements to ensure they are completely accurate. The Wealthy Venture Capitalist’s controlling parent company has been compensated $6,500 per month for 12 months by Stony Hill Corp. (STNY). The Wealthy Venture Capitalist’s controlling parent company has also been compensated 62,222 restricted common by Stony Hill Corp. (STNY). The Wealthy Venture Capitalist encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled through their website, news releases, and corporate filings, or is available from public sources and The Wealthy Venture Capitalist makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. The Private Securities Litigation Reform Act of 1995 provides investors a ‘safe harbor’ in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be “forward looking statements”. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as “projects,” “foresee,” “expects,” “will,” “anticipates,” “estimates,” “believes,” “understands,” or that by statements indicating certain actions “may,” “could,” or “might” occur. Understand there is no guarantee past performance will be indicative of future results. Past Performance is based on the security’s previous day closing price and the high of day price during our promotional coverage. Readers must visit our website at www.